Medpace Holdings, Inc. (NASDAQ:MEDP) Q1 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals concerns about increased price competition, mixed project quality, and reliance on a few customers. EBITDA margins are decreasing, and there is uncertainty in backlog growth and bookings due to cancellations. Despite share repurchases, the Q&A highlights risks like funding issues and lack of clear guidance. These factors, combined with a decrease in net new business awards, suggest a negative sentiment likely affecting stock price.
Key Financial Performance
Revenue $558.6 million, a year-over-year increase of 9.3%.
Net New Business Awards $500 million, a decrease of 18.8% from the prior year.
Ending Backlog $2.8 billion, a decrease of 2.1% from the prior year.
EBITDA $118.6 million, an increase of 2.6% compared to $115.7 million in Q1 2024.
EBITDA Margin 21.2%, down from 22.6% in the prior year, impacted by employee-related costs and foreign exchange.
Net Income $114.6 million, an increase of 11.7% compared to $102.6 million in the prior year.
Net Income per Diluted Share $3.67, compared to $3.20 in the prior year.
Cash Flow from Operating Activities $125.8 million.
Cash $441.4 million.
Share Repurchases Approximately 1.19 million shares or $389.8 million.
Remaining Share Repurchase Authorization $344.8 million.
Net Days Sales Outstanding Negative 67.8 days.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Revenue Growth: Revenue for the first quarter of 2025 was $558.6 million, which represents a year-over-year increase of 9.3%.
Backlog: Ending backlog as of March 31, 2025, was approximately $2.8 billion, a decrease of 2.1% from the prior year.
Net New Business Awards: Net new business awards entering backlog in the first quarter decreased 18.8% from the prior year to $500 million.
Guidance for 2025 Revenue: Full year 2025 total revenue is now expected in the range of $2.14 billion to $2.24 billion, representing growth of 1.5% to 6.2% over 2024 total revenue of $2.11 billion.
EBITDA Margin: EBITDA margin for the first quarter was 21.2% compared to 22.6% in the prior year period.
Cash Flow from Operations: In the first quarter, we generated $125.8 million in cash flow from operating activities.
Share Repurchase: During the first quarter, we repurchased approximately 1.19 million shares or $389.8 million.
Book-to-Bill Ratio: Net book-to-bill ratio of 0.90, with expectations of improving to above 1.15 in Q3 and Q4.
Customer Concentration: Top five and top ten customers represented roughly 22% and 32% respectively, of first quarter 2025 revenue.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Net Awards and Book-to-Bill Ratio: Net awards were down sequentially and year over year, with a net book-to-bill ratio of 0.90, primarily due to high pipeline cancellations in prior quarters.
Backlog Cancellations: Backlog cancellations were modestly elevated in Q1, with pre-backlog cancellations being worse, impacting future projected backlog net awards.
RFP Flow and Quality: RFP flow was strong in Q1, but the quality was variable and decisions are slowing, which could affect future business.
Economic Climate: Future backlog growth and book-to-bill ratios depend on moderating cancellations and an improved business climate.
EBITDA Margin: EBITDA margin decreased to 21.2% from 22.6% in the prior year, impacted by employee-related costs and foreign exchange due to a weakening US dollar.
Customer Concentration: Top five and top ten customers represented roughly 22% and 32% of revenue respectively, indicating potential risk from customer concentration.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Net Book-to-Bill Ratio: The net book-to-bill ratio was 0.90, reflecting high pipeline cancellations in prior quarters.
Backlog Growth: The company anticipates improved backlog growth with book-to-bill ratios above 1.15 in Q3 and Q4, contingent on moderating cancellations and an improved business climate.
2025 Total Revenue Guidance: Full year 2025 total revenue is expected in the range of $2.14 billion to $2.24 billion, representing growth of 1.5% to 6.2% over 2024.
2025 EBITDA Guidance: 2025 EBITDA is expected in the range of $462 million to $492 million, representing a decline of 3.8% to growth of 2.5% compared to 2024.
2025 Net Income Guidance: Forecasted net income for 2025 is in the range of $378 million to $402 million.
Earnings Per Diluted Share Guidance: Earnings per diluted share is expected to be in the range of $12.26 to $13.04.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Repurchase: In the first quarter, we repurchased approximately 1.19 million shares or $389.8 million. At the end of the quarter, we had $344.8 million remaining under our share repurchase authorization program.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Are you seeing more price competition and is that a little bit of what you mean when you say the quality is a little more mixed?
A:Yes, there’s more price competition and a broader look at CROs during a slowdown. The quality of RFPs is mixed due to funding issues and the stage of projects.
Q:What would be required to achieve a 1.15 book-to-bill in the second half?
A:We have visibility on opportunities that could convert into backlog, but we need to avoid large cancellations and have projects move into operational execution.
Q:What do you think bookings look like if you don’t get that improved climate?
A:It’s difficult to predict; it depends on how bad the environment gets. If cancellations continue, we might be around 1.0 book-to-bill.
Q:Can you provide any detail around your rare disease exposure and the FDA's discussion about doing less trials?
A:That’s hypothetical. If trials are easier, it could lead to more development, but I don’t see it as a risk to our industry.
Q:Can you remind us what your cancellation rate is?
A:We don’t disclose cancellation rates, but cancellations have been broad, largely due to funding issues.
Q:What would trigger Medpace to get more aggressive on share repurchases?
A:We’ll continue to take an opportunistic approach and look for opportunities to repurchase shares.
Q:Do you have any sense for how much of your small biopharma exposure is negative enterprise value?
A:We don’t track negative EV values, but funding difficulties are a bigger issue than drug failures.
Q:Is the turnover at the FDA impacting your client discussions?
A:It makes everyone worried about the future, but there’s no evidence of delays or changes in behavior yet.
Q:What is the outlook on turnover and hiring this year?
A:We’re targeting mid-single-digit headcount growth, but it depends on how the environment unfolds.
Q:Are you seeing any clients having funding issues due to pulled commitments from backers?
A:Yes, that’s part of it. Clients often represent they have funding, but the strength of those commitments can vary.
Q:Can you give us a sense of the relative mix between pre-backlog cancellations and backlog cancellations?
A:Pre-backlog cancellations were significantly worse, while backlog cancellations were within a normal range.
Q:What are your thoughts on the dynamics of backlog burn?
A:It’s more a function of revenue acceleration and lower bookings, not due to changes in execution.
Q:What are the dynamics behind the increase in pass-through revenue?
A:The increase is driven by complexity at sites, inflation, and scarcity of patients.
Q:How should we think about the pass-through influence on revenue versus your prior expectation?
A:The revenue increase was influenced by reimbursement activity, which was higher than expected.
Q:Review of Unclear Management Responses
A:Management avoided providing specific cancellation rates and metrics on negative enterprise value, indicating they do not disclose such data. Additionally, responses regarding the impact of FDA turnover and future revenue guidance lacked clarity and specific details.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Brady remark
CFO Brady
Form Ks
Holdings Inc
Inc Conference
Inc conference
Ks filing
Medpace Director
Medpace Holdings
President CFO
Relations Medpace
Transcript day
award RFP
backlog decrease
bill ratio
cancellation climate
climate comment
comment increase
concentration cash
conference Medpace
day cash
decision path
decline income
decrease margin
dollar income
measure release
mode speaker
period decrease
phone queue
press star
queue press
session press
share authorization
speaker answer
star phone
star reminder
weakening dollar
website Troendle
MEDP Transcript
Medpace Holdings, Inc. (MEDP) Q4 2025 Earnings Call Transcript
Unknown2-10
The earnings call presented a mixed picture: strong revenue growth expectations were offset by high cancellation rates and unclear management responses on key issues like AI impact and M&A environment. While product development and market strategy showed some positive signs, concerns over pass-through costs and the lack of specific guidance on cancellation trends and burn rate create uncertainties. The absence of a new partnership announcement or major shareholder return plan further tempers positive sentiment, resulting in a neutral outlook for the stock price over the next two weeks.
Medpace Holdings, Inc. (MEDP) Q3 2025 Earnings Call Transcript
Positive10-23
The earnings call summary indicates strong revenue guidance with a raised outlook, optimistic backlog conversion, and a strategic shift to faster growing therapeutic areas. Despite slower EBITDA growth, the overall sentiment is positive due to improved funding confidence, a strong pre-backlog position, and expected acceleration in hiring. While some uncertainties remain, particularly around cancellations and competition, the positive aspects outweigh them, suggesting a likely stock price increase over the next two weeks.
Medpace Holdings, Inc. (MEDP) Q2 2025 Earnings Call Transcript
Unknown7-22
The earnings call summary indicates mixed signals: improved backlog growth and low cancellations are positive, but the weak win rate and dependency on low cancellations for future success are concerning. The Q&A reveals management's reluctance to provide specific long-term guidance, adding uncertainty. Despite improved productivity and revenue growth, reliance on pass-through revenue and potential headwinds in 2025 suggest caution. These factors, combined with management's vague responses, lead to a neutral sentiment, anticipating minimal stock price movement.
Medpace Holdings, Inc. (NASDAQ:MEDP) Q1 2025 Earnings Call Transcript
Unknown4-23
The earnings call reveals concerns about increased price competition, mixed project quality, and reliance on a few customers. EBITDA margins are decreasing, and there is uncertainty in backlog growth and bookings due to cancellations. Despite share repurchases, the Q&A highlights risks like funding issues and lack of clear guidance. These factors, combined with a decrease in net new business awards, suggest a negative sentiment likely affecting stock price.
MEDP Slides
MEDP Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
